ARN-509 (apalutamide)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ARN-509 (apalutamide), covering 2025-03-04 to 2025-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate [Phase 1]